{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000241","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.439579+00:00","generated_at":"2026-05-30T09:25:38.866361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Chemed Q3: rev $606M (+7.4%), adj EPS $5.64; FY2024 adj EPS guidance cut to $23.00-$23.15 on Roto-Rooter weakness","bullets":["GAAP diluted EPS $5.00 (+1.4%); adjusted diluted EPS $5.64 (+6.0%).","VITAS net patient revenue $391.4M (+17.3%), ADC 21,785 (+15.5%), adjusted EBITDA $73.1M (+33.1%).","Roto-Rooter revenue $214.8M (-6.9%), adjusted EBITDA $56.4M (-15.8%), margin 26.3% (-275 bps).","FY2024 adjusted EPS guidance revised to $23.00-$23.15 (targeting 13.3%-14.0% growth over 2023) due to softer Roto-Rooter results.","Repurchased 100,000 shares for $57.8M at $578.21/share; cash $238.5M, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000241","json":"https://secwatch.observer/filing/0001562762-24-000241.json","markdown":"https://secwatch.observer/filing/0001562762-24-000241.md","text":"https://secwatch.observer/filing/0001562762-24-000241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000241/0001562762-24-000241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000241/che-20241029x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:25:38.866361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}